Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
Genmab A/S (GMAB) recently announced positive trial results for Epkinly in DLBCL, a type of non-Hodgkin lymphoma. This news puts the spotlight on whether the stock's current valuation fully reflects the potential commercial upside of this therapeutic advance.
What happened
Genmab A/S (GMAB) recently announced positive trial results for Epkinly in DLBCL, a type of non-Hodgkin lymphoma.
The read · Jul 8
The market is weighing whether Genmab's (GMAB) valuation accurately reflects the upside potential from the positive Epkinly DLBCL trial results.
Wrong if
Regulatory hurdles or slower-than-expected commercial uptake of Epkinly in the DLBCL indication could limit upside. Competitive pressures in the oncology space are also a factor.
CoverageSource: Yahoo Finance · Published here WED, JUL 8 · 11:04 AM ET · the only report in this recordHow this is decided →
The chart · GMABTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Genmab A/S (GMAB) reported positive results from its clinical trial for Epkinly (epcoritamab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This is a significant development for the company, as Epkinly is a bispecific antibody developed in collaboration with AbbVie and is already approved for other indications.
The positive trial results could expand Epkinly's addressable market and solidify its position in the competitive oncology landscape. The drug's efficacy in DLBCL, a challenging cancer to treat, suggests a strong commercial opportunity.
Now, the market is evaluating whether GMAB's stock price, which currently reflects a company with $21.5B in revenue and 30.7% YoY growth, has fully priced in the potential sales boost and improved outlook from this expanded indication. The question is whether the market has adequately discounted the future revenue streams and profit margins (currently 36.4% net) that Epkinly could generate in this new segment.
Traders will be watching for analyst updates and management commentary on the regulatory path and commercialization strategy for Epkinly in DLBCL. The stock's performance will likely hinge on how quickly and effectively Genmab can translate these positive trial results into market share and revenue growth, especially considering its current P/E multiple relative to peers and growth prospects.
The read, in fullWhy it matters
Positive trial results for Epkinly in DLBCL represent a material expansion of the drug's market potential for Genmab. With $21.5B in revenue and 30.7% YoY growth already, this new indication could drive further top-line expansion and margin improvement given the 36.4% net margin. The stock appears undervalued if the market hasn't fully priced in this additional revenue stream.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUL 8 on
Next · what would move this
2-4 weeks. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+13.7%
JUL 8 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
The positive Epkinly DLBCL trial results suggest a significant expansion of the drug's addressable market, which, given Genmab's existing $21.5B revenue and 30.7% YoY growth, could lead to increased revenue and justify a higher valuation.
▼ The case it breaks
The current stock price may already reflect a substantial portion of the expected commercial success for Epkinly, and any delays in regulatory approval or intense competition could cap upside, especially if the market has over-extrapolated the impact of these trial results.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →